PTLA Portola Pharmaceuticals, Inc.

36.72
-1.21  -3%
Previous Close 37.93
Open 37.90
Price To book 13.38
Market Cap 2.09B
Shares 57,020,000
Volume 563,723
Short Ratio 4.00
Av. Daily Volume 848,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
Phase 2 enrolment commenced May 2016. Continues to enroll as of November 2016.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
CRL August 17 2016
Andexanet alfa
Factor Xa inhibitor reversal agent

Latest News

  1. ETFs with exposure to Portola Pharmaceuticals, Inc. : May 22, 2017
  2. Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 22, 2017
  3. These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop?
  4. Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
  5. Edited Transcript of PTLA earnings conference call or presentation 8-May-17 8:30pm GMT
  6. 3 Top Biotech Stocks For May
  7. Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  8. Why Portola Pharmaceuticals Shot 12.8% Higher Today
  9. Portola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : May 9, 2017
  10. Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
  11. Portola Pharmaceuticals posts 1Q loss
  12. Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  13. Investor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call
  14. Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
  15. Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017
  16. Losing Money on a Stock? Blame Your Brain
  17. ETFs with exposure to Portola Pharmaceuticals, Inc. : April 5, 2017
  18. 3 Hot Stocks to Buy in April